Trials / Completed
CompletedNCT03950960
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants
An Open-label, Single-Sequence, 2-Treatment Period Study to Investigate the Effects of Cytochrome P450 3A4 Inhibition by Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of cytochrome P450 3A4 inhibition by Itraconazole on the pharmacokinetics of BMS-986256.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986256 | Specified dose on specified days |
| DRUG | Itraconazole | Specified dose on specified days |
Timeline
- Start date
- 2019-05-02
- Primary completion
- 2019-07-31
- Completion
- 2019-08-07
- First posted
- 2019-05-15
- Last updated
- 2020-02-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03950960. Inclusion in this directory is not an endorsement.